公司資料
Selecta 股價、新聞與催化劑
- 股票代碼:
- SELB
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股價為何變動
Current closing-price context is not available for SELB.
公司概覽
業務概覽
Selecta Biosciences was a biotechnology company focused on immune tolerance and engineered nanoparticles before becoming a historical ticker. Its story centered on using immunology science to create more precise biologic therapies.
所在地與產業分類
Selecta was headquartered in the United States and listed on NASDAQ. It sat in platform biotechnology and immunology.
商業模式特徵
The company depended on clinical data, translational validation, and capital support. Investors historically watched proof-of-concept and strategic development.
生技產業定位
Selecta belongs to the historical immunology-platform bucket. It was a science-heavy small-cap name where valuation depended on whether the platform could truly differentiate.
未來催化劑
- Selecta’s catalysts are SEL-212 and the gout / immunology program, plus any strategic update that clarifies the company’s future. The company still needs a cleaner clinical or corporate path.
近期新聞
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。